The purpose of this study is to compare the efficacy and safety of ICP-332 in moderate to severe chronic spontaneous urticaria subjects inadequately controlled by second generation H1-antihistamines
1. Men and women aged 18 to 75 years.
2. Diagnosis of CSU inadequately controlled by second generation H1-antihistamines.
3. CSU duration for ≥ 6 months prior to randomization.
4. Before initiating any screening or study-specific procedures, the subject must voluntarily sign the informed consent form.
1. Having the other medical conditions related to CSU or other skin diseases/conditions.
2. Potential medical conditions or issues.
3. Pregnant female subjects or lactating female subjects.
4. The investigator determines that the subject is unsuitable for participating in this study for any reason.
6
Treatment groupsSee each treatment group below.